## **Special Issue**

# Pharmacogenetics to Avoid Adverse Drug Reactions

## Message from the Guest Editor

Dear colleagues, Although a cure is the main goal of a treatment, serious adverse reactions associated with these treatments are a major problem in clinical practice and cost a lot of money for health systems. These adverse reactions limit the success of medicines and can even lead to the death of patients. Identifying the DNA variants associated with adverse drug reactions can help to personalize medicine and sustain health systems. This Special Issue focuses on these topics: the identification of DNA variants associated with adverse drug reactions, clinical application, and cost-effectiveness studies.

## **Guest Editor**

Dr. Luis A. López-Fernández

Hospital Pharmacy and Pharmacogenomics, Instituto de Investigación Sanitaria Gregorio Marañón, Servicio de Farmacia, Hospital General Universitario Gregorio Marañón, Madrid, Spain

## Deadline for manuscript submissions

closed (1 July 2021)



# Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



## mdpi.com/si/55645

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/

jpm





# Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



## About the Journal

## Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on "omics"-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical

subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

## Editor-in-Chief

## Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2. Canada

## **Author Benefits**

## **High Visibility:**

indexed within Scopus, PubMed, PMC, Embase, and other databases.

## Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

## **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

